Young woman with diffi cult-to-treat chronic migraine

• Published in: Contemporary pediatrics (Montvale, N.J.) Vol. 36; no. 1; pp. 40 - 41
• Main Author: Hackethal, Veronica
• Format: Journal Article
• Language: English
• Published: Monmouth Junction MultiMedia Healthcare Inc 01.01.2019
• Subjects: Bipolar disorder; Birth control; Migraine; Pediatrics; Womens health; United States > US
• ISSN: 8750-0507; 2150-6345

"1 Moreover, in 2011, the FDA warned that children exposed to valproate in utero are at increased risk for impaired cognitive development, and in 2013, the FDA issued a statement that valproate is contraindicated for migraine prevention in pregnant women because of findings that suggest that the offspring might have a decreased IQ.3 The FDA has also advised that the benefits of valproate should be carefully weighed against the risks, and an alternative medication with lower risk to the fetus should be used if the drug is not deemed essential. Because the drug is new, insufficient evidence exists about its safety during pregnancy in humans, but animal data suggested no adverse effects to offspring. TAKE-HOME POINTS О Valproate use during pregnancy has been linked to impaired cognitive development and lower IQ in offspring, as well as several birth defects, especially neural tube defects. О The FDA has stated that valproate is contraindicated for migraine prevention in pregnant women. О The European Union has strict regulations against valproate use in women of childbearing potential, who must follow a Pregnancy Prevention Plan. О Women of childbearing potential who take valproate should adhere to effective contraception and take folic acid.